GALAPAGOS N.V. | 52.18 / +2.76% |
News
- Jyseleca® approved in Japan for ulcerative colitis
03/28/2022 / 08:01 - GlobeNewswire - Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
03/24/2022 / 21:17 - GlobeNewswire - Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
03/24/2022 / 21:01 - GlobeNewswire - Galapagos increases share capital through subscription right exercises
03/18/2022 / 22:01 - GlobeNewswire - Galapagos 2021 results set stage for future growth
02/24/2022 / 22:01 - GlobeNewswire - Galapagos receives transparency notification from EcoR1 Capital
02/03/2022 / 22:01 - GlobeNewswire - Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
02/02/2022 / 22:01 - GlobeNewswire - Galapagos creates new subscription right plan
01/26/2022 / 22:40 - GlobeNewswire - Galapagos appoints Paul Stoffels as Chief Executive Officer
01/26/2022 / 22:01 - GlobeNewswire - Historic Decree Creates a New Marine Reserve – ‘Reserva Marina de Hermandad’– near the Galapagos Islands to Protect a Massive ‘Swimway’ for Threatened Ocean Wildlife
01/15/2022 / 03:05 - GlobeNewswire - Galapagos creates new subscription right plan
01/13/2022 / 22:01 - GlobeNewswire - Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
01/06/2022 / 15:30 - GlobeNewswire - Dow Jones Celebrates 2021 Achievements
12/30/2021 / 14:00 - GlobeNewswire - Galapagos increases share capital through subscription right exercises
12/03/2021 / 22:01 - GlobeNewswire - Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
11/22/2021 / 22:01 - GlobeNewswire